Popular Articles

Pulmonary Hypertension Successfully Treated With Stem Cells
Zannos Grekos, MD, a featured speaker at the at the 17th Annual World Congress on Anti-Aging Medicine and Regenerative Biotechnologies, announced one year follow-up results for a pulmonary hypertension patient treated with his own activated stem cells.

New Method For Breast Cancer Biomarker Discovery Developed By VBI Researchers
Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.
News of the day
FDA Accepts For Review Spectrum's Response On ZEVALIN As A Class 1 Submission, And Establishes September 7, 2009 As Decision Date
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a focus on oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the resubmission to the Company"s supplement to the biologics license application for ZEVALIN (ibritumomab tiuxetan) in the first line consolidation setting on July 8, 2009. The FDA considers the review as a Class 1 submission to their complete response letter of July 2, 2009. Therefore, the user fee goal date is September 7, 2009.
Nutrition

TR BioSurgical, LLC Develops Breakthrough Osteoarthritis Implant

TR BioSurgical, LLC, announced highly encouraging results using their new medical device (bioscaffold) in canine patients with advanced osteoarthritis. The new bioscaffold is implanted in or near diseased tissue and provides a structural matrix for local repair cells, such as stem cells or fibroblasts, to attach and heal tissue by local, physiological repair mechanisms. The new bioscaffold implant contains no drugs, cells or growth factors and is eventually resorbed by the infiltrating cells. The implant is made from a proprietary, copolymerized collagen and is sterile, cost effective, and non- immunogenic. Dr. Charles Pullen, lead investigator at the Animal Medical and Surgical Center, Scottsdale, Arizona, stated, "We have been evaluating canine patients with moderate to severe degenerative joint disease and pain. Without exception the owners reported a marked improvement within seven days of implantation and continued improvement thereafter in all dogs implanted with the bioscaffold, even with the discontinuation of all arthritis drugs and supplements. Dogs which required heavy medication to walk very short distances are walking, jumping, and running long distances just as they did before the onset of osteoarthritis with just one implant procedure with the bioscaffold". Dr. Jeff Kellerman, VP of R&D at TR BioSurgical, further added, "Few would debate that veterinary medicine is long overdue for safer, more effective options for managing osteoarthritis. Many of the drugs used in veterinary medicine can have harmful side effects and achieve suboptimal clinical benefits. Our team has developed a novel, cost effective and safe bioscaffold that has achieved optimal clinical outcomes in dogs that are poorly responsive to medical management." About Canine Osteoarthritis Osteoarthritis is the leading cause of disability in dogs and is estimated to affect twenty five percent of the dog population, making it one of the single largest markets in veterinary medicine. Osteoarthritis is a complex disorder involving cartilage, subchondral bone, and synovium leading to various degrees of inflammation and physical disability. Canine arthritis can mimic the progressive inflammatory and structural changes observed in human osteoarthritis, making it an excellent comparative model for human orthopedics and degenerative joint disease. TR BioSurgical, LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):